CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion [Yahoo! Finance]
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution [Yahoo! Finance]
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CeriBell (NASDAQ:CBLL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $29.00 to $30.00. They now have a "buy" rating on the stock.